IPCA Laboratories

IPCA Laboratories Forward P/E

The Forward P/E Ratio of IPCA Laboratories (IPCALAB.NS) as of Oct 28, 2026 is 33.34. In the previous year, Forward P/E Ratio was 51.58 — a change of -35.35% (lower).

Forward P/E

33.34

YoY

-35.35%

Last updated:

Forward P/E Ratio of IPCA Laboratories is 2026 33.34 . Forward P/E Ratio of IPCA Laboratories was 2025 51.58 . It decreases by -35.35% lower compared to the previous year.

The IPCA Laboratories Forward P/E history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Forward P/E
Date
Forward P/E
Jan 1, 2019
85.54 INR
Jan 1, 2020
62.75 INR
Jan 1, 2021
33.38 INR
Jan 1, 2022
43.04 INR
Jan 1, 2023
80.73 INR
Jan 1, 2024
69.51 INR
Jan 1, 2025
51.58 INR
Jan 1, 2026
33.34 INR
The IPCA Laboratories Forward P/E history
YEARForward P/EYoY
33.34-35.35%
51.58-25.80%
69.51-13.89%
80.73+87.58%
43.04+28.95%
33.38-46.81%
62.75-26.63%
85.54-46.18%
158.92-18.75%
195.58-52.12%
408.51+172.95%
149.66+88.23%
79.51—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

IPCA Laboratories Stock analysis

What does IPCA Laboratories do? Ipca Laboratories Ltd. generates revenue through the manufacturing and marketing of over 350 pharmaceutical formulations and approximately 80 active pharmaceutical ingredients (APIs), including Atenolol, Chloroquine Phosphate, Chlorthalidone, Furosemide, Hydroxychloroquine sulfate, Losartan, Metoprolol Succinate, Metoprolol Tartrate, Pyrantel Salts, and Propranolol. The company sells its branded products such as Zerodol, Lariago, HCQS, Perinorm, Rapither AB, Tenoric, Lumerax, Etova, Fexova, Malirid, Allsuth, Alwiz, AZR 50mg, Bacilon, Cinkona, Clarbact, Glyree MV, Halotop, Luliz, Ozepam, Pacimol, Pari, Xtor-F, Zabpro, Zilast, Ramcor, Sove, and Venpower in more than 100 countries globally. Its subsidiaries, Ipca Pharmaceuticals, Inc., Ipca Laboratories (U.K.) Ltd, and Tonira Exports Limited, support the distribution and sales of these products across international markets. The company's primary customers are healthcare providers, hospitals, and pharmacies in over 100 countries, purchasing both generic APIs and branded formulations. Manufacturing units in India produce APIs and formulations, with the firm's subsidiaries facilitating global market access. The therapeutic segments covered by its products include cardiovascular, antimalarial, and gastrointestinal treatments, among others, driven by the demand for cost-effective pharmaceutical solutions. IPCA Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about IPCA Laboratories stock

Forward P/E Ratio of IPCA Laboratories is 33.34 in 2026.

Forward P/E Ratio of IPCA Laboratories changed from 51.58 to 33.34, representing a -35.35% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Forward P/E Ratio IPCA Laboratories since 2006 – with annual values, charts, and detailed analysis.

The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.

To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's IPCA Laboratories with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — IPCA Laboratories

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — IPCA Laboratories